Lyndhurst, United States
Infervision, a leading innovator in AI medical imaging solutions, has been advancing multidisciplinary healthcare since it was founded in 2016. By leveraging cutting-edge artificial intelligence, the company aims to enhance operational efficiency and patient outcomes across key healthcare processes—from disease screening and diagnosis to treatment and management.
Infervision's comprehensive suite of AI-driven solutions, including InferRead®, InferOperate®, InferCare®, and InferScholar®, addresses a wide array of medical needs, such as cancer detection, infectious disease management, and trauma care. This extensive global reach includes collaborations with over 1000 leading hospitals across North America, Europe, and Asia.
The company’s last recorded funding round was a significant $140.00M Series D investment on 23 July 2021, backed by prominent investors such as New Alliance Capital and Goldman Sachs Asset Management. Headquartered in the United States, Infervision is positioned as a global leader in AI innovation for healthcare, solidifying its role as a valued partner to hospitals, governments, and healthcare professionals worldwide.
